MEDVi vs NovoCare Pharmacy (Wegovy) (2026): prices, structure, verdict

On tirzepatide, only MEDVi↗ has a rankable figure: $399 a month all-in; NovoCare Pharmacy (Wegovy)↗ does not offer tirzepatide.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, MEDVi is cheaper: $299 versus $349 a month all-in — a $50 monthly gap, $600 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

MEDVi: the record, condensed

On tirzepatide, the number that matters at MEDVi is $399 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #14 of 17 verified programs, with the floor $184/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

On semaglutide, the number that matters at MEDVi is $299 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #18 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

NovoCare Pharmacy (Wegovy): the record, condensed

On semaglutide, the number that matters at NovoCare Pharmacy (Wegovy) is $349 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at NovoCare Pharmacy (Wegovy) is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #0 of 20 in the verified semaglutide index — $216/month above the floor (Oak Longevity, $133) — and sits $0 over the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $4,188.

Operationally at NovoCare Pharmacy (Wegovy): shipping included (or retail via savings card); commitment none; cancellation no subscription; pharmacy named (Novo Nordisk direct / retail partners); states: 50 states; evidence source-verified, captured 2026-08-10. The full record with source and archive links: the NovoCare Pharmacy (Wegovy) page · visit NovoCare Pharmacy (Wegovy) ↗

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $299 (MEDVi) against $349 (NovoCare Pharmacy (Wegovy)). $50 a month sounds survivable; $600 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $50 gap is exactly what it appears to be.

A way to feel the $50 monthly gap: over a year it funds 2.0 extra months at MEDVi’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $1,200, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: MEDVi $299/mo month-to-month against NovoCare Pharmacy (Wegovy) $349/mo month-to-month. The order holds: MEDVi leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: MEDVi $897 monthly; NovoCare Pharmacy (Wegovy) $1,047 monthly — best path favors MEDVi by $150. 6 months: MEDVi $1,794 monthly; NovoCare Pharmacy (Wegovy) $2,094 monthly — best path favors MEDVi by $300. 12 months: MEDVi $3,588 monthly; NovoCare Pharmacy (Wegovy) $4,188 monthly — best path favors MEDVi by $600. 24 months: MEDVi $7,176 monthly; NovoCare Pharmacy (Wegovy) $8,376 monthly — best path favors MEDVi by $1,200.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

§ Structure vs structure

Everything besides the price

Coverage: MEDVi publishes “priced differently in CA/NC on some plans”; NovoCare Pharmacy (Wegovy) publishes “50 states” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: NovoCare Pharmacy (Wegovy) names its network (Novo Nordisk direct / retail partners); MEDVi does not, which shifts the burden of verification onto your intake questions.

Exit terms: MEDVi — 12-month plan for the lowest rate; 12-month plan applies to lowest rate. NovoCare Pharmacy (Wegovy) — none; no subscription.

Evidence: MEDVi source-verified (captured 2026-08-05); NovoCare Pharmacy (Wegovy) source-verified (2026-08-10).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

§ If you move

Switching between MEDVi and NovoCare Pharmacy (Wegovy)

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (MEDVi: 12-month plan applies to lowest rate; NovoCare Pharmacy (Wegovy): no subscription) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings